TTM
19.4%
YoY change
+1.22pp
Trough year (2006)
-873.7%
Peak year (2025)
21.7%
Latest annual
21.7%
EBITDA Margin history chart for Insulet (PODD) from 2006 to 2025
Latest: 21.7%
EBITDA Margin change chart for Insulet (PODD) from 2006 to 2025
Latest: +1.22pp
EBITDA Margin history table for Insulet (PODD) from 2006 to 2025
| 2025 | 21.7% | +1.22pp | ||
| 2024 | 20.5% | +1.38pp | ||
| 2023 | 19.1% | +10.72pp | ||
| 2022 | 8.4% | -4.35pp | ||
| 2021 | 12.7% | +0.51pp | ||
| 2020 | 12.2% | +2.14pp | ||
| 2019 | 10.1% | +1.70pp | ||
| 2018 | 8.4% | +6.97pp | ||
| 2017 | 1.4% | +1.00pp | ||
| 2016 | 0.4% | +12.83pp | ||
| 2015 | -12.4% | -5.14pp | ||
| 2014 | -7.3% | -0.75pp | ||
| 2013 | -6.5% | +5.20pp | ||
| 2012 | -11.7% | +10.47pp | ||
| 2011 | -22.2% | +12.22pp | ||
| 2010 | -34.4% | +47.19pp | ||
| 2009 | -81.6% | +125.81pp | ||
| 2008 | -207.4% | +158.42pp | ||
| 2007 | -365.9% | +507.88pp | ||
| 2006 | -873.7% | — |
- 202521.7%+1.22pp
- 202420.5%+1.38pp
- 202319.1%+10.72pp
- 20228.4%-4.35pp
- 202112.7%+0.51pp
- 202012.2%+2.14pp
- 201910.1%+1.70pp
- 20188.4%+6.97pp
- 20171.4%+1.00pp
- 20160.4%+12.83pp
- 2015-12.4%-5.14pp
- 2014-7.3%-0.75pp
- 2013-6.5%+5.20pp
- 2012-11.7%+10.47pp
- 2011-22.2%+12.22pp
- 2010-34.4%+47.19pp
- 2009-81.6%+125.81pp
- 2008-207.4%+158.42pp
- 2007-365.9%+507.88pp
- 2006-873.7%—
EBITDA Margin values are taken from Insulet's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's latest reported EBITDA margin is 19.4%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Insulet (PODD) EBITDA margin is 21.67% – expanded 1.2 percentage points year-over-year.
2025 marks the peak EBITDA margin at 21.67%, with the historical low of -873.74% recorded in 2006.
Insulet EBITDA Margin by Year
Insulet EBITDA Margin 2025: 21.7%
2025's EBITDA margin for Insulet came in at 21.67%, expanded 1.2 percentage points from 2024. This figure represents the highest annual value in the available history.
Insulet EBITDA Margin 2024: 20.5%
Insulet posted EBITDA margin of 20.45% in 2024, expanded 1.4 percentage points from 2023.
Insulet EBITDA Margin 2023: 19.1%
In 2023, Insulet reported EBITDA margin of 19.07%, expanded 10.7 percentage points from 2022.
Insulet EBITDA Margin 2022: 8.4%
Insulet EBITDA margin in 2022 was 8.35%, contracted 4.4 percentage points from 2021.
Insulet EBITDA Margin 2021: 12.7%
Insulet EBITDA margin in 2021 was 12.70%.
See more financial history for Insulet (PODD).
Sector peers by EBITDA Margin
Healthcare peers of Insulet (PODD), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 26.9% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
- 26.9%
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation